ContraFect Corporation (CFRX) Social Stream

Featured Post From StockTwits About CFRX

$CFRX 'As such, we are now seeing effects of the pandemic on our trial, and our most recent monthly patient enrollment rate has slowed. As the pandemic evolves, we will continue to evaluate the impact of variable monthly patient enrollment rates on conducting the interim futility analysis by the end of the year," said Roger Pomerantz, M.D. President, Chief Executive Officer and Chairman of Contrafect."

Observations

1. 2H21 guidance for the announcement has now been changed to end of the year, so Oct calls are in doubt.

2. We are more likely to get the interim in 1H22 based on Delta cases still going up and good knows when they plateau.

3. Clinical.trials.gov now updates that last patient is projected to hit 60 day mark in November 2022. That means no data until 2023

4. Unless Pfizer partners up with CFRX after the interim, look for another dilution.

5. Does the interim pop the stock? Yes but that means a dilute on the good news, assuming it pops the stock.